Newsroom
BRIDGING SCIENCE AND PATIENTS
Media
From Bench to Bedside: The Story about BBT-401
This is the story all about science, discovery and development of BBT-401, the first-in-class Pellino-1 inhibitor. BBT-401, an experimental drug for ulcerative colitis (UC) is in the Phase 2a in the United States.
2020.06.25
